{"count": 15, "results": [{"_id": "35884965", "pmid": 35884965, "pmcid": "PMC9313388", "title": "Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease", "journal": "Biomedicines", "authors": ["Dalbøge LS", "Christensen M", "Madsen MR", "Secher T", "Endlich N", "Drenic' V", "Manresa-Arraut A", "Hansen HH", "Rune I", "Fink LN", "Østergaard MV"], "date": "2022-07-11T00:00:00Z", "doi": "10.3390/biomedicines10071661", "meta_date_publication": "2022 Jul 11", "meta_volume": "10", "meta_issue": "7", "meta_pages": "", "score": 50261.168, "text_hl": "Co-administration of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ further ameliorated @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@. ", "citations": {"NLM": "Dalbøge LS, Christensen M, Madsen MR, Secher T, Endlich N, Drenic' V, Manresa-Arraut A, Hansen HH, Rune I, Fink LN, Østergaard MV. Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease Biomedicines. 2022 Jul 11;10(7):. PMID: 35884965", "BibTeX": "@article{35884965, title={Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease}, author={Dalbøge LS and Christensen M and Madsen MR and Secher T and Endlich N and Drenic' V and Manresa-Arraut A and Hansen HH and Rune I and Fink LN and Østergaard MV}, journal={Biomedicines}, volume={10}, number={7}}"}}, {"_id": "34180715", "pmid": 34180715, "title": "Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.", "journal": "Am J Physiol Renal Physiol", "authors": ["Østergaard MV", "Secher T", "Christensen M", "Salinas CG", "Roostalu U", "Skytte JL", "Rune I", "Hansen HH", "Jelsing J", "Vrang N", "Fink LN"], "date": "2021-08-01T00:00:00Z", "doi": "10.1152/ajprenal.00154.2021", "meta_date_publication": "2021 Aug 1", "meta_volume": "321", "meta_issue": "2", "meta_pages": "F149-F161", "score": 50257.375, "text_hl": "@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ significantly improved @DISEASE_Albuminuria @DISEASE_MESH:D000419 @@@albuminuria@@@, @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@, @DISEASE_Nephritis_Interstitial @DISEASE_MESH:D009395 @@@tubulointerstitial injury@@@, and @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@. ", "citations": {"NLM": "Østergaard MV, Secher T, Christensen M, Salinas CG, Roostalu U, Skytte JL, Rune I, Hansen HH, Jelsing J, Vrang N, Fink LN. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161. PMID: 34180715", "BibTeX": "@article{34180715, title={Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.}, author={Østergaard MV and Secher T and Christensen M and Salinas CG and Roostalu U and Skytte JL and Rune I and Hansen HH and Jelsing J and Vrang N and Fink LN}, journal={Am J Physiol Renal Physiol}, volume={321}, number={2}, pages={F149-F161}}"}}, {"_id": "39181397", "pmid": 39181397, "title": "Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.", "journal": "Kidney Int", "authors": ["Karreci ES", "Jacas S", "Donovan O", "Pintye D", "Wiley N", "Zsengeller ZK", "Schlondorff J", "Alper SL", "Friedman DJ", "Pollak MR"], "date": "2024-08-22T00:00:00Z", "doi": "10.1016/j.kint.2024.07.026", "meta_date_publication": "2024 Aug 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50256.793, "text_hl": "@DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@Proteinuria@@@ reduction and @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@ in G2/G2 BAC-transgenic @SPECIES_10090 @@@mice@@@ required @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ doses two times higher than were effective in G1/G1 @SPECIES_10090 @@@mice@@@ but achieved a much smaller benefit. ", "citations": {"NLM": "Karreci ES, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller ZK, Schlondorff J, Alper SL, Friedman DJ, Pollak MR. Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2. Kidney Int. 2024 Aug 22;():. PMID: 39181397", "BibTeX": "@article{39181397, title={Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.}, author={Karreci ES and Jacas S and Donovan O and Pintye D and Wiley N and Zsengeller ZK and Schlondorff J and Alper SL and Friedman DJ and Pollak MR}, journal={Kidney Int}}"}}, {"_id": "35767209", "pmid": 35767209, "title": "Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension.", "journal": "Geroscience", "authors": ["Williams JM", "Murphy SR", "Wu W", "Border JJ", "Fan F", "Roman RJ"], "date": "2022-12-01T00:00:00Z", "doi": "10.1007/s11357-022-00610-7", "meta_date_publication": "2022 Dec", "meta_volume": "44", "meta_issue": "6", "meta_pages": "2845-2861", "score": 50249.184, "text_hl": "Blood @DISEASE_Pressure_Ulcer @DISEASE_MESH:D003668 @@@pressure@@@ and @DISEASE_Hypertrophy @DISEASE_MESH:D006984 @@@renal hypertrophy@@@ were also reduced in @SPECIES_10116 @@@rats@@@ treated with @CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@empagliflozin@@@ and @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@. Administration of @CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@empagliflozin@@@ alone or in combination with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ lowered @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@blood glucose@@@, @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@, and @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@renal fibrosis@@@ but had no effect on blood @DISEASE_Pressure_Ulcer @DISEASE_MESH:D003668 @@@pressure@@@, kidney weight, or @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DN@@@ @SPECIES_10116 @@@rats@@@. ", "citations": {"NLM": "Williams JM, Murphy SR, Wu W, Border JJ, Fan F, Roman RJ. Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension. Geroscience. 2022 Dec;44(6):2845-2861. PMID: 35767209", "BibTeX": "@article{35767209, title={Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension.}, author={Williams JM and Murphy SR and Wu W and Border JJ and Fan F and Roman RJ}, journal={Geroscience}, volume={44}, number={6}, pages={2845-2861}}"}}, {"_id": "39577983", "pmid": 39577983, "title": "Has APOL1 kidney disease treatment been hiding in plain sight?", "journal": "Kidney Int", "authors": ["Olabisi OA"], "date": "2024-12-01T00:00:00Z", "doi": "10.1016/j.kint.2024.09.003", "meta_date_publication": "2024 Dec", "meta_volume": "106", "meta_issue": "6", "meta_pages": "1015-1017", "score": 50247.473, "text_hl": "In this issue, Sula Karreci et al. reported that @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ reduced @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@ and @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@ in a @SPECIES_10090 @@@mouse@@@ model of @GENE_APOL1 @GENE_8542 @@@apolipoprotein L1@@@-induced @DISEASE_Glomerulosclerosis_Focal_Segmental @DISEASE_MESH:D005923 @@@focal segmental glomerulosclerosis@@@, in a genotype-specific manner. ", "citations": {"NLM": "Olabisi OA. Has APOL1 kidney disease treatment been hiding in plain sight? Kidney Int. 2024 Dec;106(6):1015-1017. PMID: 39577983", "BibTeX": "@article{39577983, title={Has APOL1 kidney disease treatment been hiding in plain sight?}, author={Olabisi OA}, journal={Kidney Int}, volume={106}, number={6}, pages={1015-1017}}"}}, {"_id": "32605800", "pmid": 32605800, "title": "Sodium thiosulfate improves renal function and oxygenation in L-NNA-induced hypertension in rats.", "journal": "Kidney Int", "authors": ["Nguyen ITN", "Klooster A", "Minnion M", "Feelisch M", "Verhaar MC", "van Goor H", "Joles JA"], "date": "2020-08-01T00:00:00Z", "doi": "10.1016/j.kint.2020.02.020", "meta_date_publication": "2020 Aug", "meta_volume": "98", "meta_issue": "2", "meta_pages": "366-377", "score": 50241.12, "text_hl": "Combining @CHEMICAL_Thiosulfates @CHEMICAL_MESH:D013885 @@@thiosulfate@@@ with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ further lowered renal vascular resistance (mean 43 vs. 63 mmHg/ml/min/100 gbw) and prevented @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@. ", "citations": {"NLM": "Nguyen ITN, Klooster A, Minnion M, Feelisch M, Verhaar MC, van Goor H, Joles JA. Sodium thiosulfate improves renal function and oxygenation in L-NNA-induced hypertension in rats. Kidney Int. 2020 Aug;98(2):366-377. PMID: 32605800", "BibTeX": "@article{32605800, title={Sodium thiosulfate improves renal function and oxygenation in L-NNA-induced hypertension in rats.}, author={Nguyen ITN and Klooster A and Minnion M and Feelisch M and Verhaar MC and van Goor H and Joles JA}, journal={Kidney Int}, volume={98}, number={2}, pages={366-377}}"}}, {"_id": "12138278", "pmid": 12138278, "title": "Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis.", "journal": "Nephron", "authors": ["Shinosaki T", "Miyai I", "Nomura Y", "Kobayashi T", "Sunagawa N", "Kurihara H"], "date": "2002-08-01T00:00:00Z", "doi": "10.1159/000065036", "meta_date_publication": "2002 Aug", "meta_volume": "91", "meta_issue": "4", "meta_pages": "719-29", "score": 50075.844, "text_hl": "The present study was performed to clarify the mechanism underlying the beneficial effects of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ on @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@chronic glomerulonephritis@@@. ", "citations": {"NLM": "Shinosaki T, Miyai I, Nomura Y, Kobayashi T, Sunagawa N, Kurihara H. Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron. 2002 Aug;91(4):719-29. PMID: 12138278", "BibTeX": "@article{12138278, title={Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis.}, author={Shinosaki T and Miyai I and Nomura Y and Kobayashi T and Sunagawa N and Kurihara H}, journal={Nephron}, volume={91}, number={4}, pages={719-29}}"}}, {"_id": "16395266", "pmid": 16395266, "title": "ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.", "journal": "Kidney Int", "authors": ["Remuzzi A", "Gagliardini E", "Sangalli F", "Bonomelli M", "Piccinelli M", "Benigni A", "Remuzzi G"], "date": "2006-04-01T00:00:00Z", "doi": "10.1038/sj.ki.5000060", "meta_date_publication": "2006 Apr", "meta_volume": "69", "meta_issue": "7", "meta_pages": "1124-30", "score": 50066.47, "text_hl": "@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ significantly reduced incidence and extent of @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@, with the presence of glomerular tufts not affected by @DISEASE_Sclerosis @DISEASE_MESH:D012598 @@@sclerosis@@@ (23% of glomeruli). ", "citations": {"NLM": "Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 2006 Apr;69(7):1124-30. PMID: 16395266", "BibTeX": "@article{16395266, title={ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.}, author={Remuzzi A and Gagliardini E and Sangalli F and Bonomelli M and Piccinelli M and Benigni A and Remuzzi G}, journal={Kidney Int}, volume={69}, number={7}, pages={1124-30}}"}}, {"_id": "10081615", "pmid": 10081615, "title": "Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.", "journal": "Clin Exp Pharmacol Physiol", "authors": ["Kai T", "Sugimura K", "Shimada S", "Kurooka A", "Ishikawa K"], "date": "1999-03-01T00:00:00Z", "doi": "10.1046/j.1440-1681.1999.03023.x", "meta_date_publication": "1999 Mar", "meta_volume": "26", "meta_issue": "3", "meta_pages": "206-11", "score": 50061.02, "text_hl": "The @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@ index was significantly lowered by @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, but the index in the @CHEMICAL_Hydralazine @CHEMICAL_MESH:D006830 @@@hydralazine@@@ group was not significantly different from that in the untreated group. 4. ", "citations": {"NLM": "Kai T, Sugimura K, Shimada S, Kurooka A, Ishikawa K. Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. Clin Exp Pharmacol Physiol. 1999 Mar;26(3):206-11. PMID: 10081615", "BibTeX": "@article{10081615, title={Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.}, author={Kai T and Sugimura K and Shimada S and Kurooka A and Ishikawa K}, journal={Clin Exp Pharmacol Physiol}, volume={26}, number={3}, pages={206-11}}"}}, {"_id": "10598677", "pmid": 10598677, "title": "Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis.", "journal": "J Pharmacol Toxicol Methods", "authors": ["Wapstra FH", "van Goor H", "de Jong PE", "Navis G", "de Zeeuw D"], "date": "1999-04-01T00:00:00Z", "doi": "10.1016/s1056-8719(99)00015-5", "meta_date_publication": "1999 Apr-Jun", "meta_volume": "41", "meta_issue": "2-3", "meta_pages": "69-73", "score": 50058.54, "text_hl": "@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ resulted in a significantly lower @<m>DISEASE_Glomerulonephritis</m> @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@ score in the 2-mg/kg @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@doxorubicin@@@ group only (16+/-15, p<0.05), whereas the 3-mg/kg group showed no significant reduction (56+/-29, NS). ", "citations": {"NLM": "Wapstra FH, van Goor H, de Jong PE, Navis G, de Zeeuw D. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J Pharmacol Toxicol Methods. 1999 Apr-Jun;41(2-3):69-73. PMID: 10598677", "BibTeX": "@article{10598677, title={Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis.}, author={Wapstra FH and van Goor H and de Jong PE and Navis G and de Zeeuw D}, journal={J Pharmacol Toxicol Methods}, volume={41}, number={2-3}, pages={69-73}}"}}]}